Send to

Choose Destination
Mov Disord Clin Pract. 2018 Jan-Feb;5(1):47-53. doi: 10.1002/mdc3.12553. Epub 2017 Sep 22.

Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort.

Author information

Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO USA.
Department of Neurology, Aurora St. Luke's Medical Center, Milwaukee, WI.
Neurology Section, Denver VA Medical Center, Denver, CO USA.



The Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UDPRS) is a commonly used tool to measure Parkinson disease (PD) progression. Longitudinal changes in MDS-UPDRS scores in de novo PD have not been established.


Determine progression rates of MDS-UPDRS scores in de novo PD.


362 participants from the Parkinson's Progression Markers Initiative, a multicenter longitudinal cohort study of de novo PD, were included. Longitudinal progression of MDS-UPDRS total and subscale scores were modeled using mixed model regression.


MDS-UPDRS scores increased in a linear fashion over five years in de novo PD. MDS-UPDRS total score increased an estimated 4.0 points/year, Part I 0.25 points/year, Part II 1.0 points/year, and Part III 2.4 points/year.


The expected average progression of MDS-UPDRS scores in de novo PD from this study can assist in clinical monitoring and provide comparative data for detection of disease modification in treatment trials.


MDS-UPDRS; Parkinson disease; biomarkers; disease progression

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center